



Hepatitis B Virus (HBV) Infection and Vaccine

Guest Editor:

Dr. Irina Sominskaya

Latvian Biomedical Research and
Study Centre, Ratsupites 1, LV-
1067 Riga, Latvia

Deadline for manuscript
submissions:

15 September 2024

Message from the Guest Editor

According to The Institut Pasteur data, hepatitis B is one of the most prevalent human diseases. It is estimated that two billion people have been infected by the virus. Chronic infection with hepatitis B virus (HBV) develops in millions of patients every year, despite the availability of effective prophylactic vaccines that can prevent hepatitis B. Chronic carriers have a high risk of dying from cirrhosis or liver cancer. These diseases cause about 887,000 deaths annually. The existing vaccines have proven to be highly effective in preventing HBV infection, but ongoing research aims to improve their efficacy, duration of protection, and accessibility. These vaccines are less effective in certain groups of people such as aged and obese people or are ineffective in chronic HBV carriers.

Therefore, the Special Issue aims to provide a collection of articles that highlight recent advancements in the field of hepatitis B. As the Guest Editor of this Special Issue, I invite you to submit research articles, review articles, and short communications related to Hepatitis B infection as well as to prophylactic and therapeutic vaccine development against this virus.





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Nico Jehmlich

Department of Molecular
Systems Biology, UFZ-Helmholtz
Centre for Environmental
Research, 04318 Leipzig,
Germany

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*Microbiology*)

Contact Us

Microorganisms Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/microorganisms
microorganisms@mdpi.com
X@Micro_MDPI